Jocasta Neuroscience: $35 Million Series A Raised For Advancing Longevity Protein Program
By Amit Chowdhry ● Aug 13, 2025
Jocasta Neuroscience is a company focused on improving longevity. Its main product is a special formulation of the protein alpha-Klotho, which may help treat cognitive issues linked to neurodegenerative diseases. The company recently raised $35 million in a Series A financing round. True Ventures, an early-stage venture capital firm, led the funding, with contributions from Moore Strategic Ventures, SC8 Investments, Glentura, the Yagan Family Foundation, and others. Kevin Rose from True Ventures will join Dr. Michael Davidson, the Chair of the Board, and Dr. Albert Agro, the CEO, on the Board of Directors.